NONINSULIN ANTIHYPERGLYCEMIC AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES Self-Assessment Answers and Rationales
1. The correct answer is c. Rationale: Based on the 2023 American Diabetes Association (ADA) Standards of Care for patients with type 2 diabetes, when compared to sulfonylureas, metformin is first-line therapy if the medication is tolerated and the patient’s A1C is not over 10% (ElSayed et al., 2023a).
2. The correct answer is b. Rationale: Sulfonylureas are noninsulin antihyperglycemic agents that work by stimulating the release of insulin from pancreatic beta cells.
NONINSULIN ANTIHYPERGLYCEMIC AGENTS FOR THE TREATMENT OF TYPE 2 DIABETES Final Examination Questions Select the best answer for each question and mark your answers on the Final Examination Answer Sheet found on page 123, or complete your test online at EliteLearning.com/Book
56. John is a 55-year-old who had prediabetes for a year and has now been diagnosed with type 2 diabetes. His medical history indicates he has chronic obstructive pulmonary disease and is unable to tolerate sulfasalazine (Azulfidine). What antihyperglycemic agent could be used in John’s situation? a. Glipizide. b. Glucophage. c. Pioglitazone. d. Sitgliptin. 57. Which class of noninsulin antihyperglycemic agents increases insulin sensitivity? 58. Mrs. D is 67 years old with type 2 diabetes and advanced chronic kidney disease. Which class of drugs is protective for the kidneys and helpful in managing glycemia? a. Sulfonylureas. b. Biguanides. c. DPP-4. d. SGLT-2 inhibitors. 59. Which of the following is the most common side effect for Glucophage (metformin)? a. Lactic acidosis. b. Diarrhea. c. Rhinitis. d. Hypoglycemia. 60. Which of the following noninsulin antihyperglycemic classes exerts its effect by inhibiting an enzyme that breaks down glucose for absorption? a. Alpha-glucosidase inhibitors. b. Biguanides. c. GLP-1 receptor agonists. d. DPP-4 inhibitors. a. Meglitinides. b. Biguanides. c. Thiazolidinediones. d. DPP-4 inhibitors.
61. Mr. R has been taking pioglitazone for over a year. Which of the following is linked to taking pioglitazone for over a year? a. Esophageal cancer. b. Bladder cancer. c. Kidney failure. d. Loss of effectiveness of the drug. 62. Which statement about dipeptidyl peptidase (DPP-4) inhibitors is correct? a. DPP-4s are typically administered twice daily. b. DPP-4s are given by injection. c. DPP-4s extend incretin hormone action time. d. DPP-4s must be taken with food. 63. Which of the following phrases describes meglitinides medications? a. Rapid-acting nonsulfonylurea secretagogues taken with meals. b. Act primarily in the liver to limit hepatic glucose output. c. Cause a higher rate of hyperglycemia than sulfonylurea medications. d. Take up to 12 weeks to reach the desired response. 64. Which of the following anti-insulin antihyperglycemic agents is most appropriately paired with an adverse side effect and its use? a. Canagliflozin – lactic acidosis. b. Glucophage – urinary tract infections. c. Repaglinide – hypoglycemia. d. Liraglutide – constipation. 65. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that: a. Increases glucagon secretion. b. Stimulates glucose-induced insulin secretion. c. Increases gastric motility. d. Is slowly metabolized by DPP-4.
Course Code: RPTTX02NA
EliteLearning.com/Pharmacy-Technician
Book Code: RPTTX2024
Page 75
Powered by FlippingBook